Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Change in Cash (2018 - 2025)

Historic Change in Cash for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$318.3 million.

  • Takeda Pharmaceutical's Change in Cash rose 8752.09% to -$318.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $964.0 million, marking a year-over-year decrease of 2488.97%. This contributed to the annual value of -$402.4 million for FY2025, which is 4306.28% up from last year.
  • Takeda Pharmaceutical's Change in Cash amounted to -$318.3 million in Q4 2025, which was up 8752.09% from $2.2 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Change in Cash peaked at $3.1 billion during Q1 2021, and registered a low of -$2.9 billion during Q2 2021.
  • In the last 5 years, Takeda Pharmaceutical's Change in Cash had a median value of -$202.8 million in 2025 and averaged -$29.7 million.
  • The largest annual percentage gain for Takeda Pharmaceutical's Change in Cash in the last 5 years was 408199.51% (2024), contrasted with its biggest fall of 131861.1% (2024).
  • Takeda Pharmaceutical's Change in Cash (Quarter) stood at $970.5 million in 2021, then tumbled by 175.43% to -$732.0 million in 2022, then skyrocketed by 75.44% to -$179.8 million in 2023, then plummeted by 1318.61% to -$2.6 billion in 2024, then skyrocketed by 87.52% to -$318.3 million in 2025.
  • Its Change in Cash stands at -$318.3 million for Q4 2025, versus $2.2 billion for Q3 2025 and -$225.8 million for Q2 2025.